Mon, 01 Jun 2015 12:00:00 GMT ~ Matinas BioPharma's MAT9001 Meets Primary and Secondary Endpoints in First Human Trial versus Vascepa(R)
[GlobeNewswire] - -- MAT9001 demonstrates superiority versus Vascepa on bioavailability, triglyceride reduction and other lipid endpoints -- -- MAT9001 is the first orally-administered dyslipidemia product reported to significantly ...
Thu, 28 May 2015 11:05:00 GMT ~ Matinas BioPharma to Present at the LD Micro Invitational on June 2, 2015
[GlobeNewswire] - BEDMINSTER, N.J. -- Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company") (OTCQB:MTNB), a clinical-stage biopharmaceutical company principally focused on the development ...
Tue, 26 May 2015 11:35:00 GMT ~ Matinas BioPharma to Present at the Fourth Annual SeeThru Equity Microcap Investor Conference on May 28, 2015
[GlobeNewswire] - BEDMINSTER, N.J. -- Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company") (OTCQB:MTNB), a clinical-stage biopharmaceutical company principally focused on the development ...
Wed, 20 May 2015 12:35:00 GMT ~ Antifungals, an Overlooked Biotech Niche With Big Potential
[Accesswire] - CORAL GABLES, FL / ACCESSWIRE / May 20, 2015 / If a global competition were held for the planet's most sadly ironic places, the hospital would place very high, if not win outright. This is not only true ...
Link: http://www.otcmarkets.com/stock/MTNB/company-info Ticker: $MTNB OTC Market Place: OTCQB CIK code: 0001582554 Company name: Matinas Biopharma Holdings, Inc. Company website: http://www.matinasbiopharma.com Incorporated In: DE, USA
Business Description: Matinas BioPharma is a clinical stage biopharmaceutical company, founded in 2011, focused on the development of targeted therapeutics using our innovative lipid-based drug delivery platform with an initial focus on the treatment of serious fungal and bacterial infections and the development of lipid-based prescription therapeutics for the treatment of cardiovascular and metabolic conditions. We are focused on creating highly differentiated, safe and efficacious therapies utilizing our expertise in drug formulation and development in order to address significant unmet medical needs. Recent additions to our product pipeline, including MAT2203 and MAT2501, position Matinas BioPharma to become a leader in the safe and effective delivery of anti-infective therapies utilizing its proprietary lipid-crystal nano-particle cochleate formulations. We also continue to develop our cardiovascular therapeutic candidates, with a focus on completing our ongoing PK/PD study with MAT9001, which has the goal of determining superior bioavailability and enhanced efficacy over a leading therapy for hypertriglyceridemia, as well as developing a product candidate resulting from our MAT8800 discovery program for the treatment of non-alcoholic fatty liver disease. For more information, please visit www.matinasbiopharma.comLess >>
$MTNB share structure
## source: otcmarkets.com
Market Value: $62,590,737 a/o Jun 02, 2015 Shares Outstanding: 56,900,670 a/o Apr 28, 2015 Float: 40,534,760 a/o Apr 28, 2015 Authorized Shares: 150,000,000 a/o Mar 19, 2015 Par Value: Not Available
$MTNB extra dd links
Company name: Matinas Biopharma Holdings, Inc. Company website: http://www.matinasbiopharma.com